Author Affiliations: School of Medicine and Public Health, Salvador, Brazil (Dr Correia); and School of Medicine, Federal University of Bahia, Bahia, Brazil (Dr Lopes).
We read with great interest the article by Uchino and Hernandez.1 By performing a meta-analysis of 7 randomized trials, they suggested that dabigatran therapy is associated with increased risk of myocardial infarction (MI) or acute coronary syndrome (ACS). Even though meta-analyses provide strong evidence for efficacy and safety, the role of chance should always be taken into account before definite conclusions.
Correia LCL, Lopes AA. Dabigatran and Myocardial Infarction: Meta-Illusion?. Arch Intern Med. 2012;172(10):823-823. doi:10.1001/archinternmed.2012.836